Rationale for the use of immunomodulatory therapies in the Global Initiative for Asthma (GINA) step V asthma other than oral glucocorticosteroids
Identifieur interne : 001517 ( Main/Exploration ); précédent : 001516; suivant : 001518Rationale for the use of immunomodulatory therapies in the Global Initiative for Asthma (GINA) step V asthma other than oral glucocorticosteroids
Auteurs : C. Domingo [Espagne, Canada] ; A. Moreno [Espagne] ; R. Mirapeix [Espagne]Source :
- Internal Medicine Journal [ 1444-0903 ] ; 2011-07.
English descriptors
- Teeft :
- Allergic asthma, Allergy, Allergy clin immunol, Asthma, Asthma exacerbations, Asthma patients, Asthmatic, Australasian, Bone mineral density, Bronchial asthma, Chronic asthma, Clin, Clinical effectiveness, Clinical relevance, Clinical symptoms, Cochrane, Corticoid, Corticoid dependency, Corticoid dose period, Corticosteroid, Cyclosporin, Dbpc, Domingo, Dos, Exacerbation, Fev1, Folate, Gina, Gina step, Global initiative, Gold salts, High doses, Immunoglobulin, Immunol, Immunomodulatory, Immunosuppressive, Immunosuppressive drugs, Inhaled, Inhaled corticoids, Inhaled corticosteroids, Liver toxicity, Long term, Medicine journal, Methotrexate, Mullarkey, National heart, Omalizumab, Open study, Oral corticoid dose, Oral corticoids, Oral corticosteroid, Oral corticosteroid dose, Oral corticosteroids, Oral steroids, Parc taul, Patients duration, Placebo, Primary outcome, Pulmonary function tests, Respir, Respir crit care, Rheumatoid arthritis, Royal australasian college, Severe asthma, Steroid, Therapeutic approach, Toxicity, Troleandomycin, Weekly doses.
Abstract
Asthma is a major problem worldwide, which is estimated to affect 300 million individuals. The global prevalence ranges from 1% to 18% of the population. The incidence, morbidity and mortality of the condition have increased over the last 50 years despite the development of new anti‐asthmatic drugs. Fewer than 1% of the asthmatic population are steroid‐dependent, but these patients consume most of the resources and time at asthma units. The consensus documents published by professional societies all support a stepwise therapeutic approach for asthma. However, patients who require frequent or continuous oral corticosteroid administration have received little attention. Due to the severe side‐effects of oral corticosteroids when administered over long periods or at high doses, many drugs have been assessed in the search for a possible corticosteroid‐sparing agent. Recently, the update of the Global Initiative for Asthma (GINA) introduced a new drug – omalizumab – as an alternative to oral corticosteroids in patients included in step V. Other alternatives include immunosuppressive drugs, among which methotrexate has been found to offer the best benefit/risk ratio. This paper will review, comment and criticize the evidence of the effectiveness of immunomodulatory drugs, as an alternative to oral glucocorticosteroid treatment in GINA step V asthma patients. The experience of the authors combined with the information of the literature will lead to the conclusion that methotrexate and omalizumab are the only advisable drugs and will clarify when and how these drugs should be used.
Url:
DOI: 10.1111/j.1445-5994.2011.02481.x
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 001B68
- to stream Istex, to step Curation: 001B68
- to stream Istex, to step Checkpoint: 000493
- to stream Main, to step Merge: 001519
- to stream Main, to step Curation: 001517
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Rationale for the use of immunomodulatory therapies in the Global Initiative for Asthma (GINA) step V asthma other than oral glucocorticosteroids</title>
<author><name sortKey="Domingo, C" sort="Domingo, C" uniqKey="Domingo C" first="C." last="Domingo">C. Domingo</name>
</author>
<author><name sortKey="Moreno, A" sort="Moreno, A" uniqKey="Moreno A" first="A." last="Moreno">A. Moreno</name>
</author>
<author><name sortKey="Mirapeix, R" sort="Mirapeix, R" uniqKey="Mirapeix R" first="R." last="Mirapeix">R. Mirapeix</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:4C4AAE8B489492D1D8468C8B5DD01EC5C22F41BD</idno>
<date when="2011" year="2011">2011</date>
<idno type="doi">10.1111/j.1445-5994.2011.02481.x</idno>
<idno type="url">https://api.istex.fr/ark:/67375/WNG-JLVM0LSK-X/fulltext.pdf</idno>
<idno type="wicri:Area/Istex/Corpus">001B68</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">001B68</idno>
<idno type="wicri:Area/Istex/Curation">001B68</idno>
<idno type="wicri:Area/Istex/Checkpoint">000493</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">000493</idno>
<idno type="wicri:doubleKey">1444-0903:2011:Domingo C:rationale:for:the</idno>
<idno type="wicri:Area/Main/Merge">001519</idno>
<idno type="wicri:Area/Main/Curation">001517</idno>
<idno type="wicri:Area/Main/Exploration">001517</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main">Rationale for the use of immunomodulatory therapies in the Global Initiative for Asthma (GINA) step V asthma other than oral glucocorticosteroids</title>
<author><name sortKey="Domingo, C" sort="Domingo, C" uniqKey="Domingo C" first="C." last="Domingo">C. Domingo</name>
<affiliation wicri:level="3"><country>Espagne</country>
<placeName><settlement type="city">Barcelone</settlement>
<region nuts="2" type="region">Catalogne</region>
</placeName>
<wicri:orgArea>Pulmonary Service, Corporació Parc Taulí, Sabadell</wicri:orgArea>
</affiliation>
<affiliation></affiliation>
<affiliation wicri:level="1"><country wicri:rule="url">Canada</country>
</affiliation>
</author>
<author><name sortKey="Moreno, A" sort="Moreno, A" uniqKey="Moreno A" first="A." last="Moreno">A. Moreno</name>
<affiliation wicri:level="3"><country>Espagne</country>
<placeName><settlement type="city">Barcelone</settlement>
<region nuts="2" type="region">Catalogne</region>
</placeName>
<wicri:orgArea>Pulmonary Service, Corporació Parc Taulí, Sabadell</wicri:orgArea>
</affiliation>
<affiliation><wicri:noCountry code="no comma">Departments of Medicine</wicri:noCountry>
</affiliation>
</author>
<author><name sortKey="Mirapeix, R" sort="Mirapeix, R" uniqKey="Mirapeix R" first="R." last="Mirapeix">R. Mirapeix</name>
<affiliation wicri:level="4"><country xml:lang="fr">Espagne</country>
<wicri:regionArea>Morphological Sciences, Universitat Autònoma de Barcelona (UAB), Barcelona</wicri:regionArea>
<placeName><settlement type="city">Barcelone</settlement>
<region nuts="2" type="region">Catalogne</region>
</placeName>
<orgName type="university">Université autonome de Barcelone</orgName>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j" type="main">Internal Medicine Journal</title>
<title level="j" type="alt">INTERNAL MEDICINE JOURNAL</title>
<idno type="ISSN">1444-0903</idno>
<idno type="eISSN">1445-5994</idno>
<imprint><biblScope unit="vol">41</biblScope>
<biblScope unit="issue">7</biblScope>
<biblScope unit="page" from="525">525</biblScope>
<biblScope unit="page" to="536">536</biblScope>
<biblScope unit="page-count">12</biblScope>
<publisher>Blackwell Publishing Asia</publisher>
<pubPlace>Melbourne, Australia</pubPlace>
<date type="published" when="2011-07">2011-07</date>
</imprint>
<idno type="ISSN">1444-0903</idno>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">1444-0903</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="Teeft" xml:lang="en"><term>Allergic asthma</term>
<term>Allergy</term>
<term>Allergy clin immunol</term>
<term>Asthma</term>
<term>Asthma exacerbations</term>
<term>Asthma patients</term>
<term>Asthmatic</term>
<term>Australasian</term>
<term>Bone mineral density</term>
<term>Bronchial asthma</term>
<term>Chronic asthma</term>
<term>Clin</term>
<term>Clinical effectiveness</term>
<term>Clinical relevance</term>
<term>Clinical symptoms</term>
<term>Cochrane</term>
<term>Corticoid</term>
<term>Corticoid dependency</term>
<term>Corticoid dose period</term>
<term>Corticosteroid</term>
<term>Cyclosporin</term>
<term>Dbpc</term>
<term>Domingo</term>
<term>Dos</term>
<term>Exacerbation</term>
<term>Fev1</term>
<term>Folate</term>
<term>Gina</term>
<term>Gina step</term>
<term>Global initiative</term>
<term>Gold salts</term>
<term>High doses</term>
<term>Immunoglobulin</term>
<term>Immunol</term>
<term>Immunomodulatory</term>
<term>Immunosuppressive</term>
<term>Immunosuppressive drugs</term>
<term>Inhaled</term>
<term>Inhaled corticoids</term>
<term>Inhaled corticosteroids</term>
<term>Liver toxicity</term>
<term>Long term</term>
<term>Medicine journal</term>
<term>Methotrexate</term>
<term>Mullarkey</term>
<term>National heart</term>
<term>Omalizumab</term>
<term>Open study</term>
<term>Oral corticoid dose</term>
<term>Oral corticoids</term>
<term>Oral corticosteroid</term>
<term>Oral corticosteroid dose</term>
<term>Oral corticosteroids</term>
<term>Oral steroids</term>
<term>Parc taul</term>
<term>Patients duration</term>
<term>Placebo</term>
<term>Primary outcome</term>
<term>Pulmonary function tests</term>
<term>Respir</term>
<term>Respir crit care</term>
<term>Rheumatoid arthritis</term>
<term>Royal australasian college</term>
<term>Severe asthma</term>
<term>Steroid</term>
<term>Therapeutic approach</term>
<term>Toxicity</term>
<term>Troleandomycin</term>
<term>Weekly doses</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Asthma is a major problem worldwide, which is estimated to affect 300 million individuals. The global prevalence ranges from 1% to 18% of the population. The incidence, morbidity and mortality of the condition have increased over the last 50 years despite the development of new anti‐asthmatic drugs. Fewer than 1% of the asthmatic population are steroid‐dependent, but these patients consume most of the resources and time at asthma units. The consensus documents published by professional societies all support a stepwise therapeutic approach for asthma. However, patients who require frequent or continuous oral corticosteroid administration have received little attention. Due to the severe side‐effects of oral corticosteroids when administered over long periods or at high doses, many drugs have been assessed in the search for a possible corticosteroid‐sparing agent. Recently, the update of the Global Initiative for Asthma (GINA) introduced a new drug – omalizumab – as an alternative to oral corticosteroids in patients included in step V. Other alternatives include immunosuppressive drugs, among which methotrexate has been found to offer the best benefit/risk ratio. This paper will review, comment and criticize the evidence of the effectiveness of immunomodulatory drugs, as an alternative to oral glucocorticosteroid treatment in GINA step V asthma patients. The experience of the authors combined with the information of the literature will lead to the conclusion that methotrexate and omalizumab are the only advisable drugs and will clarify when and how these drugs should be used.</div>
</front>
</TEI>
<affiliations><list><country><li>Canada</li>
<li>Espagne</li>
</country>
<region><li>Catalogne</li>
</region>
<settlement><li>Barcelone</li>
</settlement>
<orgName><li>Université autonome de Barcelone</li>
</orgName>
</list>
<tree><country name="Espagne"><region name="Catalogne"><name sortKey="Domingo, C" sort="Domingo, C" uniqKey="Domingo C" first="C." last="Domingo">C. Domingo</name>
</region>
<name sortKey="Mirapeix, R" sort="Mirapeix, R" uniqKey="Mirapeix R" first="R." last="Mirapeix">R. Mirapeix</name>
<name sortKey="Moreno, A" sort="Moreno, A" uniqKey="Moreno A" first="A." last="Moreno">A. Moreno</name>
</country>
<country name="Canada"><noRegion><name sortKey="Domingo, C" sort="Domingo, C" uniqKey="Domingo C" first="C." last="Domingo">C. Domingo</name>
</noRegion>
</country>
</tree>
</affiliations>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001517 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001517 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Sante |area= ChloroquineV1 |flux= Main |étape= Exploration |type= RBID |clé= ISTEX:4C4AAE8B489492D1D8468C8B5DD01EC5C22F41BD |texte= Rationale for the use of immunomodulatory therapies in the Global Initiative for Asthma (GINA) step V asthma other than oral glucocorticosteroids }}
This area was generated with Dilib version V0.6.33. |